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Abstract—This paper reports on the development of an 
interactive, intraoperative dose planning system for seed implant 
brachytherapy in cancer treatment. This system involves in-vivo 
dosimetry and the ability to determine implanted seed positions. 
The first stage of this project is the development of a urethral 
alarm probe to measure the dose along the urethra during a 
prostate brachytherapy treatment procedure. Ultimately the 
system will be used to advise the physicians upon reaching a 
preset dose rate or dose after total seed decay in urethra during 
the seed placement. The second stage is the development of a 
method and instrumentation for in-vivo measurements of the 
location of implanted seeds in the same frame as for dose 
planning, and using these in intraoperative treatment planning.  
We have developed a silicon mini-detector and 
preamplifier/amplifier system to satisfy the spectroscopic 
requirements of the urethral probe. This technique will avoid 
complications related to overdosing the urethra and the rectum.  
 
I. INTRODUCTION 
EAL-TIME transrectal ultrasound guided transperineal 
placement of permanent interstitial 125I and 103Pd sources is 
one of the treatment modalities available for early stage 
prostate cancer. There has been a rapid expansion of the use of 
this procedure, which is set to become the most common 
treatment modality for early stage prostate cancer. Equivalent 
biochemical control rates for low risk prostate cancer with 
permanent seed implantation in comparison to radical 
prostatectomy or external beam radiotherapy have been 
confirmed [1,2]. These biochemical outcomes have been 
favourable, but there has been little emphasis on the evaluation 
and comparison of side effects and complications. Interstitial 
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brachytherapy exhibits a different side effect profile than 
radical prostatectomy or external beam radiotherapy. 
Specifically, acute urinary side effects predominate in 
interstitial prostate brachytherapy [3,4,5]. Urinary symptoms, 
resulting in an increase of the International Prostate Symptom 
Score (IPSS), are well-recognized side effects of interstitial 
prostate brachytherapy, however more detailed evaluation of 
these symptoms has been lacking. Wallner et al. [6] observed 
an increase in grade-3 late urethral toxicity when the urethral 
dose exceeded 400Gy. Recent recommendations by the 
American Brachytherapy Society (ABS) for reporting 
morbidity after prostate brachytherapy, request urethral doses 
be recorded for correlation with urethral toxicity [7]. The ABS 
recommends that doses be obtained at the centre of the urethra, 
in half-centimeter intervals, from the base to the apex of the 
prostate, reporting the maximum and mean obtained doses [7]. 
 
 Medical complications associated with interstitial prostate 
brachytherapy can result from errors in seed placement during 
insertion. There are several factors that may lead to the 
misplacement of seeds. The guiding needles may diverge 
during insertion as different layers of tissue are penetrated [8], 
resulting in the incorrect deposition of seeds, the seeds may 
drift along the path of the needles, blood flow may alter the 
seed positions, oedema may alter the size and shape of the 
prostate, and gland motion may occur [9]. There is a need for 
seed locations to be monitored in real-time during insertion 
(intraoperatively). If a seed is misplaced, the required locations 
of other seeds may be recalculated in compensation. 
Intraoperative localization of inserted seeds will also provide a 
method of online dosimetry. Many difficulties have been 
encountered in the development of an inter-active planning 
system in the operating theatre in prostate brachytherapy [10]. 
Current commercial systems use ultrasound visualization of 
individual seeds or needles to predict the dose within the 
prostate during treatment [11]. These systems are expensive, 
have problems with artifacts as on 2D ultrasound seed imaging 
and are unable to precisely determine individual seed 
placement during a treatment procedure. The Memorial Sloan-
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Kettering Cancer Center (MSKCC) has developed an 
intraoperative conformal optimization and planning system (I-
3D) for ultrasound-based transperineal prostate implants [12]. 
Optimal operation of this system requires accurate and 
reproducible real-time position co-ordinates of each 
successively implanted seed. The MSKCC has also recently 
developed an intraoperative dosimetry system for prostate 
brachytherapy based on the combination of two imaging 
techniques [13]. Ultrasound images are obtained of the prostate 
and lead markers. Fluoroscopic images of the implanted seeds 
and lead markers are also obtained. The seed locations 
obtained from the fluoroscopic images are superimposed onto 
the prostate images using computer reconstruction. The entire 
process takes approximately 10 minutes [13]. 
 
 Here we propose the development of an alternative 
intraoperative dosimetry system based on miniature solid-state 
detectors used in spectroscopy mode. Brachytherapy seeds 
contain radioactive sources, usually 125I or 103Pd. These 
radioactive sources emit low energy photons with a distinct 
energy spectrum, at very low dose rates that are hard to 
measure with conventional detectors in confined spaces. The 
ability of solid-state detectors to resolve these energies is 
improving as new detector technologies are being developed. 
At these low energies, approximately 27 keV for 125I, most 
energy loss occurs through the photoelectric effect. The 
Compton scattering cross-section is significant, but energy loss 
due to the Compton effect is minimal. The attenuation 
coefficient for low energy photons in tissue decreases with an 
increase in energy. Spectral peaks of different energies will be 
attenuated by different amounts as the emitted photons 
penetrate the tissue. Using this principle, the ratio of peak 
heights or area under the peaks in an obtained spectrum will 
yield the distance from a measured seed to the detector. If the 
distance to one detector is known, the triangulation of 
distances from a non-coplanar array of detectors will yield the 
seed position. Such a system will be intraoperative, and will 
allow online dosimetry of the treatment. 
II. MATERIALS AND METHODS 
Monte Carlo simulations and experimental measurements 
were performed on an OncoSeed number 6711 from 
Amersham Health [14]. This seed consists of radioactive 125I, 
absorbed onto a silver rod, encapsulated in a hollow titanium 
cylinder with welded ends. The geometry of the seed was 
obtained from Williamson [15]. The silver rod is 3mm in 
length and 0.5mm in diameter. A 1-micrometer thick coating 
of silver halide is present on the rod. The radioactive iodine 
was assumed to be at the midpoint of the silver halide coating. 
The titanium shell was 4.5mm in length, 0.8mm in diameter, 
was 0.06mm thick along the sides and 0.5mm thick at the end 
welds. 125I decays via electron capture, emitting photons of 
several distinct energies through gamma and X-ray emission. 
Internal conversion and Auger electrons are also emitted, but 
were neglected, as they would not penetrate the titanium shell. 
A 3.6keV photon was also neglected. 
 
TABLE I 
6711 SEED PHOTON EMISSION [16] 
Energy (keV) Mean number/disintegration 
35.492 0.0666 
31.877 0.0438 
30.980 0.201 
27.472 0.756 
27.202 0.405 
 
Due to the presence of silver in the seed, silver fluorescent X-
rays of energies 22.1keV and 25.2keV are also present [17].  
 
Monte Carlo simulations were performed using EGSnrcV2 
[18]. The FLURZnrc user code was used to simulate the 6711 
seed in a liquid water phantom. The energy spectrum was 
obtained at various locations for distances up to 5cm from the 
seed centre at various angles around the seed. The area under 
each photon peak was measured for each obtained spectrum. 
The ratios of peak areas were calculated for the 27keV peak, 
the 31keV peak and the 35keV peak. These obtained peak 
ratios were plotted vs. distance from the seed and angle about 
the seed axis. An algorithm relating peak ratio to seed location 
was then constructed. 
 
Given that we have a method for determining the distance 
from a seed to a detector, if we have four or more non-coplanar 
detectors, we can then determine the location of the seed. For 
example, if we have 'n' detectors, each at a known location ri, 
and the distance between a seed and each detector determined 
from analysis of the spectrum is si, then we may determine the 
seed location from minimization of the following function 
{ } 
=
−−•−
n
i
iii s
1
2)()( rrrr                                             (8) 
The location r, which minimizes this, is then the estimate of 
the seed location.  
 
III.  RESULTS 
From Fig.  2 it can be seen that the photon peaks in the 
energy spectrum of the 6711 seed are very sharp, with very 
little scattering, even after the photons have traversed 5cm of 
liquid water. This allows the use of spectroscopy for analyzing 
the radiation throughout the prostate during interstitial 
brachytherapy. The areas under the 27keV, 31keV and 35keV 
peaks were measured for each obtained spectra and plots of 
ratio vs. distance along the transverse axis of the seed were 
obtained. 
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Fig.  2.  FLURZnrc energy spectrum of 6711 seed, measured 5cm from 
seed along the transverse axis. 
 
 
 
Fig.  3.  Ratio of the area under the 27keV peak to the area under the 35keV 
peak vs. distance along the transverse axis for the 6711 seed, obtained from the 
FLURZnrc spectra. 
 
 
 
Fig.  4.  Ratio of the area under the 31keV peak to the area under the 35keV 
peak vs. distance along the transverse axis for the 6711 seed, obtained from the 
FLURZnrc spectra 
 
Since scattering is minimal and the majority of energy loss 
occurs through the photoelectric effect the area under each 
peak as a function of distance may be given by 
2
0 / reAA
rµ−=                                                                   (1) 
where A is the area under a single peak, A0 is the area at zero 
distance, µ is an effective attenuation coefficient of the 
medium for photons of the peak energy and r is the distance 
from the seed to the point of measurement. The ratio of the 
area under two peaks, a and b, may be given by 
rbaba eRR µ∆−= /0
/                                                                (2) 
where Ra/b is the ratio of the area under peak a to the area 
under peak b, R0a/b is the peak ratio at zero distance and ∆µ is 
the difference in attenuation coefficients (µa-µb). Using (2) and 
the data obtained from the FLURZnrc simulations of the 6711 
seed in water, the following equations were devised. 
reR 093.035/27 41.14 −= ± 3%                                               (3) 
reR 036.035/31 39.3 −=  ± 4%                                                (4) 
The distance to a 6711 seed within liquid water may be 
calculated by measuring the ratio of the area underneath two 
peaks in the spectrum and using (3) or (4). This assumes the 
point of measurement is along the transverse axis of the seed. 
 
 The previous calculations were repeated for spectra obtained 
at different angles around a 6711 seed in a water phantom. A 
plot of R27/35 vs. distance was obtained in Fig.  5. 
 
 
Fig.  5.  The ratio of the area under the 27keV peak to the area under the 
35keV peak vs. distance for a 6711 seed in a water phantom, calculated at 
various angles around the seed. 90° represents measurements along the 
transverse axis of the seed 
 
It can be seen that the peak ratios vary with changes in source 
angle. This is due to the variation in thickness of the titanium 
shell around the seed. Photons at lower angles traverse a 
greater thickness of titanium, increasing the attenuation, 
lowering the peak ratios. Simply finding the ratio of any two 
peaks in a measured spectrum is not enough to determine the 
distance to the seed. The peak ratios are a function of both 
distance and angle. Assuming the distance from the source is 
the order of centimeters the peak ratios may be represented as 
separable functions of both distance and angle, 
)()(0 θgrfRR =                                                               (5) 
where f(r) is the distance dependent function of the peak ratio 
and g(θ) is the angular dependent function of the peak ratio. 
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f(r) was previously found to be e- ∆µr. To determine the angular 
dependent function of the peak ratios, g(θ), the peak ratios vs. 
angle were plotted for a fixed distance of 1cm, and normalized. 
 
Fig.  6.  Normalized plot of R27/35 vs. angle to determine the function 
g(θ)27/35. Ratios were calculated 1cm from the seed centre.  
 
 
Fig.  7.  Normalized plot of R31/35 vs. angle to determine the function 
g(θ)31/35. Ratios were calculated 1cm from the seed centre. 
 
After taking into account the angular variance in peak ratios, 
(3) and (4) become 
)(41.14 093.035/27 θgeR r−=  ± 5%                                      (6) 
)(39.3 036.035/31 θgeR r−=  ± 6%.                                      (7) 
By calculating the area under the 27keV, 31keV and 35keV 
peaks for an obtained spectrum, performing ratios of the 
obtained areas and solving (6) and (7) simultaneously, the 
distance to the seed as well as the angle of the seed to the point 
of measurement may be determined. 
 
In order to determine the practicality of this approach for 
determining seed positions we have conducted simulations 
where seeds are placed at random in a specified cubical 
volume. Four detectors are placed in a tetrahedral 
configuration. The distances between each detector and a given 
seed are determined. These distances are then varied randomly 
to simulate the effects of noise and uncertainties due to seed 
anisotropy, etc. These uncertain distances are then used, along 
with the known detector positions, in the equation (8) above. 
The position r, which minimizes this, is determined by the 
downhill simplex method [19], and compared to the seed 
location. The accuracy of this method for locating seeds is a 
function of treatment volume, tetrahedron size, and the 
assumed magnitude of uncertainties in seed-detector distances. 
Table II gives results for trials of one million seed positions in 
cubes of various edge lengths. These have been chosen to span 
the range of treatment volumes, even though the shape differs 
from a typical prostate. 
 
 The results of Table II show that the proportion of times 
that a large seed location error occurs is sensitive to the 
precision with which the seed-detector distances can be 
determined. An increase in this by a factor of 2.5 results in an 
increase by the same factor in the average error, but the 
proportion of times an error of greater than 2.5mm occurs 
increases by a much greater factor. 
 
                        TABLE  II 
ERRORS IN SEED LOCATION 
Cube 
edge 
length 
(mm) 
Tetrahedron 
edge length 
(mm) 
Average 
error 
(mm) 
Percentage 
greater 
than 
2.5mm 
Error (%) 
in seed-
detector 
distance 
4.5 3.0 1.8 18 5 
4.0 3.0 1.6 12 5 
3.5 2.5 1.4 7 5 
3.0 2.5 1.2 3 5 
4.5 2.5 0.72 0.12 2 
4.0 2.5 0.63 0.011 2 
3.5 2.5 0.56 0.0003 2 
3.0 2.5 0.49 0.0012 2 
 
 
Stage 1 in the development of an in vivo dosimetry and seed 
localization system is the construction of the urethra alarm 
probe. This uses spectroscopy to estimate the dose to the 
urethra during interstitial brachytherapy treatment. The probe 
consists of a silicon mini-detector of dimensions 0.8mm x 
0.8mm x 3mm. This is connected to a preamplifier/amplifier 
system by a thin 40cm cable, allowing the placement of the 
detector within the prostate via a urinary catheter. The probe 
was used to measure the spectrum of a 6711 seed in air at 
25°C, while connected to the amplifier system via a 40cm 
cable that would be used in practice. 
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Fig.  8.  6711 seed spectrum, measured with the Urethra Alarm Probe 
connected to the preamplifier via a 40cm cable. The 27keV peak is well 
resolved. The 31keV and 35keV peaks are well resolved but do not contain 
many counts. Also present is the 22keV silver X-ray peak. The 27keV peak is 
outlined and has a FWHM of 2.3keV 
 
 The 6711 seed spectrum in Fig.  8 shows that the current 
detector system does not accurately resolve the peaks 
necessary for use in seed localization. It does, however, show 
that the current system may be used for dosimetry purposes. 
The 27keV peak is well resolved. Since scattering is minimal 
and most energy loss is due to the photoelectric effect, the area 
under the 27keV peak may be used to estimate the dose 
received by the detector. The probe may be placed inside the 
prostate during seed insertion to allow the physicians to ensure 
the dose received by the urethra is within tolerable limits. The 
photon spectrum of the 6711 seed was also measured with the 
photons incident on the rear of the detector. There was no 
apparent change in the measured spectrum, indicating that the 
detector was fully depleted and has an isotropic response to 
photon irradiation. 
 
IV. CONCLUSION 
The development of an intraoperative treatment planning 
system for low dose rate brachytherapy of the prostate, based 
on semiconductor detectors operating in spectroscopy mode, 
seems to be feasible. Such a system will allow updating of the 
treatment plan to correct for seed misplacement, and online 
dosimetry. A method exists for locating seeds, based on 
distances between four detectors and a seed, with each of these 
distances being determined by observation of the ratio of 
counts under different energy peaks. The determination of the 
distance from a seed to a detector is possible theoretically but 
has yet to be proven experimentally.  
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